Avodart Compounding Legal Status: What Patients and Prescribers Need to Know

Is Avodart an FDA-approved product?

Yes. The FDA record lists Avodart as dutasteride 0.5 mg capsule for oral use, marketing status prescription, therapeutic equivalence code AB, and as the reference listed drug [1]. The original approval was on November 20, 2001, submission type 1 - new molecular entity, standard review, and the application is now held by Waylis Therapeutics [1]. The current Avodart label is effective March 12, 2025 [2].

Are there approved generics?

Generic dutasteride capsules have been approved since November 20, 2015 (Aurobindo, Amneal and OneSource) [1]. The fixed-dose combination of dutasteride 0.5 mg and tamsulosin 0.4 mg is Jalyn (NDA 022460, approved June 14, 2010); an Aurobindo generic combination capsule was approved on July 18, 2024 [1].

What is Avodart approved for, and at what dose?

The approved use is symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate, to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of BPH-related surgery [2]. Avodart is also indicated in combination with the alpha blocker tamsulosin for symptomatic BPH [2]. The label states one limitation of use: Avodart is not approved for the prevention of prostate cancer [2].

For Avodart soft gelatin capsules, the labeled dose is 0.5 mg once daily, with or without food. The label says the capsule should be swallowed whole and not chewed or opened, because contact with the capsule contents may irritate the lining of the mouth and throat [2]. With tamsulosin, the label specifies dutasteride 0.5 mg once daily plus tamsulosin 0.4 mg once daily [2].

Is Avodart approved for hair loss?

No. The only approved indication is symptomatic BPH, alone or with tamsulosin, so hair loss (androgenetic alopecia) is off-label use [2]. In a 24-week randomized trial of 917 men aged 20 to 50 with androgenetic alopecia, dutasteride 0.5 mg increased hair count more than finasteride 1 mg (P=.003) and more than placebo (P<.001) [3]. The trial lasted only 24 weeks [3].

What does the Avodart label warn about?

These warnings come from the label for the approved 0.5 mg oral capsule [2].

• PSA. Dutasteride reduces serum PSA by about 50% within 3 to 6 months. The label says to establish a new PSA baseline at least 3 months after starting, to double an isolated PSA value in a man treated for 3 months or more when comparing with untreated ranges, and to evaluate any confirmed rise from the lowest on-treatment value even if it is still within the normal range [2].
• Handling during pregnancy. The label warns that women who are pregnant or may be pregnant should not handle the capsules, because dutasteride can be absorbed through the skin and could harm a male fetus. If a pregnant woman touches a leaking capsule, the label says to wash the area immediately with soap and water [2].

Where does that leave compounded dutasteride?

The FDA record and label confirm that an approved oral dutasteride capsule exists and describe its indication, dosing and warnings [1][2]. Neither sets out a rule for when a compounded dutasteride capsule, solution or gel may be prepared or dispensed, so that question stays open for any specific compounded preparation.